The Scripps Research Institute (SRI) was awarded $77 million over seven years from the National Institute of Allergy and Infectious Diseases (NIAID) to focus on developing an HIV vaccine, according to an SRI statement. NIAID, which is part of the National Institutes of Health, offered two Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) grants to support a coordinated, multidisciplinary team of researchers focused on multipronged approaches to accelerate HIV vaccine development. SRI, a large, independent, nonprofit biomedical research organization, will investigate immune responses that may be able to prevent HIV infection or suppress it in people with the virus. Specifically, scientists will study antibodies and B cells (the cells that produce antibodies) and other components of the immune system. The other CHAVI-ID grant was awarded to Duke University in Durham, North Carolina.

To read the SRI statement, click here.